

Arnold S Freedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6332819/publications.pdf>

Version: 2024-02-01

74
papers

4,316
citations

147801

31
h-index

110387

64
g-index

75
all docs

75
docs citations

75
times ranked

5361
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 1991, 325, 1525-1533.	27.0	678
2	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
3	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , 1999, 94, 3325-3333.	1.4	319
4	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
5	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
6	Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2007, 25, 2554-2559.	1.6	219
7	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	1.6	180
8	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon- γ inducible gene expression, without significant toxicity. <i>Blood</i> , 2005, 105, 489-495.	1.4	155
9	Follicular lymphoma: 2020 update on diagnosis and management. <i>American Journal of Hematology</i> , 2020, 95, 316-327.	4.1	140
10	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	1.6	132
11	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002, 117, 828-834.	2.5	131
12	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	1.4	129
13	Unbalanced Expression of Bcl-2 Family Proteins in Follicular Lymphoma: Contribution of CD40 Signaling in Promoting Survival. <i>Blood</i> , 1998, 91, 244-251.	1.4	114
14	Follicular lymphoma: 2018 update on diagnosis and management. <i>American Journal of Hematology</i> , 2018, 93, 296-305.	4.1	87
15	Phase II study of a TLR α agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 282-291.	2.5	75
16	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	1.6	75
17	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 262-268.	2.0	68
18	CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. <i>British Journal of Haematology</i> , 2002, 119, 492-495.	2.5	65

#	ARTICLE	IF	CITATIONS
19	Phase I/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lincociclimab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	2.5	65
20	Expression and regulation of CD5 on in vitro activated human B cells. <i>European Journal of Immunology</i> , 1989, 19, 849-855.	2.9	64
21	Follicular lymphoma: 2014 update on diagnosis and management. <i>American Journal of Hematology</i> , 2014, 89, 429-436.	4.1	54
22	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	2.5	51
23	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. <i>Haematologica</i> , 2014, 99, 1421-1432.	3.5	50
24	Low-Dose Involved-Field Radiation in the Treatment of Non-Hodgkin Lymphoma: Predictors of Response and Treatment Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 121-127.	0.8	49
25	Functional Effects of TNF and Lymphotoxin α on FDC-like Cells. <i>Cellular Immunology</i> , 2000, 203, 134-143.	3.0	45
26	Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. <i>Clinical Infectious Diseases</i> , 2019, 68, 247-255.	5.8	42
27	Association of the Cas-like Molecule HEF1 with CrkL Following Integrin and Antigen Receptor Signaling in Human B-Cells: Potential Relevance to Neoplastic Lymphohematopoietic Cells. <i>Leukemia and Lymphoma</i> , 1997, 28, 65-72.	1.3	40
28	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	5.2	40
29	Multicolour fluorescence <i>in situ</i> hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. <i>British Journal of Haematology</i> , 2003, 122, 745-759.	2.5	39
30	Follicular lymphoma: 2012 update on diagnosis and management. <i>American Journal of Hematology</i> , 2012, 87, 988-995.	4.1	38
31	Follicular lymphoma: 2011 update on diagnosis and management. <i>American Journal of Hematology</i> , 2011, 86, 768-775.	4.1	33
32	Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 87-93.	1.3	32
33	MCP-1 modulates chemotaxis by follicular lymphoma cells. <i>British Journal of Haematology</i> , 2001, 115, 554-562.	2.5	31
34	Biology and Management of Histologic Transformation of Indolent Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 314-320.	2.5	31
35	Follicular lymphoma: 2015 update on diagnosis and management. <i>American Journal of Hematology</i> , 2015, 90, 1171-1178.	4.1	28
36	B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. <i>Lancet Oncology</i> , 2004, 5, 711-717.	10.7	20

#	ARTICLE	IF	CITATIONS
37	High Dose Therapy and Autologous Stem Cell Transplantation in Follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1998, 28, 219-230.	1.3	18
38	Targeting constitutively active <scp>STAT3</scp> in chronic lymphocytic leukemia: A clinical trial of the <scp>STAT3</scp> inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021, 96, E95-E98.	4.1	17
39	Down-Regulation of CD9 Expression and its Correlation to Tumor Progression in B Lymphomas. <i>American Journal of Pathology</i> , 2010, 177, 377-386.	3.8	16
40	Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 315-320.	1.3	15
41	Adhesion of Follicular Lymphoma Cells to Lymphoid Germinal Centersâ€”A Potential Mechanism of Tumor Cell Homing Following Autologous Transplantation. <i>Leukemia and Lymphoma</i> , 1994, 13, 47-52.	1.3	13
42	Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 429-434.	2.0	11
43	Targeting the follicular lymphoma microenvironment through blockade of TNFÎ± with etanercept. <i>Leukemia and Lymphoma</i> , 2008, 49, 902-909.	1.3	11
44	Expression of Vascular Cell Adhesion Molecule-1 by Follicular Dendritic Cells. <i>Leukemia and Lymphoma</i> , 1995, 18, 259-264.	1.3	8
45	The Relationship of Chronic Lymphocytic Leukemia to Normal Activated B Cells. <i>Leukemia and Lymphoma</i> , 1990, 1, 293-300.	1.3	7
46	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2331-2331.	1.4	6
47	Autologous bone marrow transplantation therapy for multiple myeloma. <i>European Journal of Haematology</i> , 1989, 43, 157-163.	2.2	5
48	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
49	Phase III Trial of Active Immunotherapy (FavldÂ®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkinâ€™s Lymphoma (fNHL).. <i>Blood</i> , 2006, 108, 2756-2756.	1.4	5
50	Follicular lymphoma with bilateral testicular and epididymal involvement: Case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2005, 46, 1663-1666.	1.3	4
51	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	4
52	B-Cell Monoclonal Antibodies and Their Use in Clinical Oncology. <i>Cancer Investigation</i> , 1991, 9, 69-84.	1.3	3
53	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	1.4	3
54	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1635-1635.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011, 118, 2865-2865.	1.4	3
56	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	1.4	3
57	Rethinking Prognosis and Therapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2489-2491.	1.6	2
58	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	1.4	2
59	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007, 110, 1358-1358.	1.4	2
60	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.	1.4	2
61	Non-Transplant-Related Treatment Options in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 53-58.	2.0	1
62	Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. <i>Ecological Management and Restoration</i> , 2016, 30, 1-8.	0.4	1
63	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2875-2875.	1.4	1
64	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
65	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009, 27, e139-e140.	1.6	0
66	Infectious Complications Associated with Bendamustine Exposure in Patients with Indolent non-Hodgkin Lymphoma. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
67	Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 218-223.	2.3	0
68	Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Long Term Follow up of Two Sequential Trials with Standard Dose and High Dose CHOP Induction.. <i>Blood</i> , 2004, 104, 5243-5243.	1.4	0
69	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. <i>Blood</i> , 2006, 108, 3041-3041.	1.4	0
70	Non-Myeloablative Allogeneic Transplantation for Hodgkin's and Non-Hodgkin's Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007, 110, 3041-3041.	1.4	0
71	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 465-465.	1.4	0
72	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , 2012, 120, 1980-1980.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4567-4567.	1.4	0
74	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2015, 126, 4001-4001.	1.4	0